NDAORALTABLET
Approved
Jun 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
STALEVO 50 (carbidopa, levodopa, and entacapone) by Orion Pharma is catechol o-methyltransferase inhibitors [moa]. Approved for catechol-o-methyltransferase inhibitor [epc]. First approved in 2003.
Drug data last refreshed 8h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STALEVO 50 is a fixed-dose oral tablet combining carbidopa, levodopa, and entacapone for Parkinson's disease management. Levodopa is converted to dopamine in the brain to restore motor function, while carbidopa prevents premature conversion in the periphery and entacapone extends levodopa's duration by inhibiting catechol-O-methyltransferase (COMT). This combination reduces motor fluctuations and optimizes dopaminergic therapy in mid-stage Parkinson's patients.
$0.04MPart D
LOE ApproachingDeclining
Low Medicare spending ($40K, 39 claims in 2023) indicates niche positioning; STALEVO 50 is lowest-dose variant with limited volume, suggesting specialized rather than high-volume sales roles.
Mechanism of Action
Catechol O-Methyltransferase Inhibitors
Pharmacologic Class:
Catechol-O-Methyltransferase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Career roles on STALEVO 50 are specialized, low-volume, and declining; positioned for professionals with Parkinson's disease expertise or managed-care acumen rather than high-growth commercial development. Opportunity best suited for mid-career professionals managing brand transition through LOE rather than early-career growth roles.
Brand Manager (lifecycle management)
Worked on STALEVO 50 at Orion Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.